1	Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks
2	from 2021-2023
3	
4	Eli A. Piliper ¹ , Jonathan Reed ¹ , Alexander L. Greninger ^{1,2, #}
5	
6	
7	1 Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA
8	² Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
9	
10	[#] Corresponding author:
11	Alexander L. Greninger
12	Department of Laboratory Medicine and Pathology, University of Washington Medical Center
13	850 Republican St, Seattle, WA 98109, USA
14	Email: agrening@uw.edu
15	
16	

17 Highlights

- 18
- We report the full clinical validation of an RSV neutralization assay
- No evidence of immune debt found in Washington State RSV 2022-2023 outbreak
- Our assay offers high throughput testing applicable to vaccine/drug studies
- 22

23 Abstract

- 24 **Background:** Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization
- 25 in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened
- 26 interest in RSV immunologic surveillance, necessitating development of high-throughput assays assessing anti-RSV
- 27 neutralizing activity.
- 28 **Objectives:** We validated an RSV focus-reduction neutralization test (RSV FRNT), a high-throughput, automation-
- 29 ready neutralization assay using RSV strain A2. The assay was then used to investigate the immunity debt
- 30 hypothesis for resurgent RSV outbreaks in the 2022-2023 season.
- 31 Study design: We evaluated precision, sensitivity, specificity, linearity, and accuracy of RSV FRNT using reference
- 32 sera, contrived specimens, and clinical remnant specimens. RSV neutralizing activity of remnant serum specimens,
- 33 sampled for HSV-1/2 antibody testing during and after the COVID-19 pandemic (February and September 2022 &
- 34 2023), was measured and correlated with concurrent trends in RSV prevalence.
- 35 Results: RSV FRNT was shown to be accurate, generating reference serum neutralizing titers within 2-fold of
- 36 established assays, with a linear analytical measurement range between 20 to 4,860 ND50 and ND80 units.
- 37 Neutralizing activity measured with the assay was positively correlated with antibody titer determined via indirect
- 38 ELISA (p = 1.0, p = 0.0014). Among individuals sampled within 3 months of RSV PCR test, RSV positives had a 9.14-
- fold higher geometric mean neutralizing titer (GMT) relative to RSV PCR negatives (p = 0.09). There was no
- 40 difference in geometric mean anti-RSV neutralizing titers between sera sampled pre- and post-2023 RSV outbreak
- 41 (p = 0.93).
- 42 **Conclusions:** We validated a high-throughput assay for assessing anti-RSV neutralizing activity and found no
- 43 significant difference in neutralizing titers between pre- and post-pandemic outbreak specimens.
- 44

46 Introduction

47	RSV is one of the most common causes of lower respiratory tract infections worldwide, infecting
48	approximately 64 million people and causing at least 160,000 deaths and 3 million hospitalizations each year [1,2].
49	2023 has seen multiple revolutions in RSV disease prevention, including the FDA approval of two vaccines for older
50	adults and pregnant individuals as well as the prophylactic monoclonal antibody (mAb) nirsevimab for prevention
51	of RSV lower respiratory tract disease in neonates and infants [3,4]. In addition, the past two years have seen global
52	resurgence of aseasonal RSV infections thought to be related to limited circulation and immunity debt attributed to
53	the COVID-19 pandemic [3,5–8]. These developments necessitate monitoring population immunity and vaccine
54	immunogenicity, both best assessed by measuring neutralizing antibodies against RSV [9–12]. RSV neutralizing
55	antibody titer is a major correlate of protection, with higher neutralizing titers being associated with lower viral
56	load and reduced risk of severe RSV-induced disease [13–18].
57	The standard for neutralization assays, the plaque-reduction neutralization test (PRNT), requires 3-5 days
58	of incubation time and is less amenable to high-throughput applications [12]. An alternative is the focus-reduction
59	neutralization test (FRNT), which often requires less sample, reagent volume, and incubation time (26-30 hours) to
60	measure neutralizing titers. A RSV FRNT assay can be performed in a 96-well plate format portable to liquid
61	handlers for higher throughput and less inter- and intra-assay variability [19–22]. Strain-specific reporter viruses
62	are utilized by some FRNTs to visualize foci but require development of a recombinant virus, potentially delaying
63	efforts to implement contemporary strains in testing. A FRNT using chromogen-conjugated secondary antibodies to
64	visualize foci is easy to implement, allowing scalability for high-throughput applications such as vaccine evaluation,
65	population immunity monitoring, and testing for vaccine- and nirsevimab-resistant strains [23].
66	Here, we describe the validation of a RSV FRNT, an automation-ready, high-throughput, standardized
67	method for assessing serum neutralizing activity against RSV in clinical and research settings. In addition, we use
68	the RSV FRNT to monitor population immunity against RSV in remnant serum specimens taken before, during, and
69	after the 2022-2023 RSV outbreak.
70	

71 Materials and Methods

72 Virus and cell line

73 Assays were run with RSV A2 as the challenge virus (ATCC, VR-1516), unless otherwise specified. RSV B strain

74 WV/14617/85 (ATCC, VR-1400) challenge experiments are described in Supplemental Methods. VeroE6 cells were

75 seeded in DMEM-10 in transparent 96-well plates (Corning, 3585) at 10,000 cells/well and grown for 24 hours prior

to infection.

77 Clinical specimens

78 Plasma or sera from patients with a history of positive RT-PCR test for RSV or influenza virus since October 1, 2023

79 were obtained from University of Washington (UW) Medicine patients that were sampled during peak RSV

80 incidence (mid-November 2023 to January 2024) and no later than 40 days following PCR testing. Remnant

81 serology specimens sent for rubella IgG testing were obtained from UW Virology. Cross-sectional sera were

82 obtained from remnant specimens sent for HSV-1/2 Western Blot testing in February 2022, July 2022, February

83 2023, and July 2023 (n=47 for each timepoint). This study was approved by the UW Medicine Institutional Review

84 Board with consent waiver (STUDY00010205). Individual line-item data and metadata is provided in Table S1. For

85 individuals with recorded RSV PCR tests, time delta (in days) between serum collection and RSV PCR test date is

86 shown in Figure S1.

87 Measurement of RSV neutralizing activity

88 Microneutralization All sera were heat inactivated (HI) at 56 °C for 30 minutes prior to testing. HI serum was 89 diluted initially 10-fold by combining 10.5 µL HI serum with 94.5 µL DMEM-10. This was followed by five 3-fold 90 dilutions by serially transferring 35 µL of diluted serum into 70 µL of DMEM-10, resulting in a final dilution series 91 from 10-fold to 2430-fold and a final volume of 70 µL for each dilution. These serial dilutions of serum were diluted 92 an additional two-fold to a final volume of 140 µL with 70 µL of RSV A2, diluted to form a final of 120-250 ffu/well 93 in the assay, resulting in a final dilution series of 20-fold to 4,860-fold. Serum-virus mixtures were incubated at 37° 94 C 5% CO₂ for 1 h. 96-well plates seeded with 10,000 VeroE6 cells/well were infected with 50 µL/well of serum-virus 95 mixture in duplicate. Plates were incubated at 37° C 5% CO₂ for 26 – 30 hours before fixation. Exogenous 96 complement, typically[13,24] used to boost neutralizing signal from low-titer sera, was not used in our RSV FRNT; 97 instead, samples with neutralizing titers below the lower limit of quantitation were retested at a lower, 5-fold initial 98 dilution to obtain reportable ND50 and ND80 values within assay analytical measurement range (20-4,860).

99 Focus-forming assay Assay plates were fixed for 60 minutes at room temperature (approximately 21-25 ° C) with 25 100 μ L (1/2 well volume) of 4% formaldehyde prepared in DPBS with 100 mg/L calcium and 100 mg/L magnesium. 101 After fixation, plates were washed three times with 150 µL room-temperature 1xPBS and incubated for 2 h at room 102 temperature with 50 µL/well of mouse mAb 131-2G against RSV-A2 F-protein (Sigma-Aldrich, MAB8582) diluted 103 4000-fold in FFA staining buffer (composed of 1x PBS, 1 mg/mL saponin, and 0.1% lgG-free BSA). Plates were then 104 washed three times with 150 µL room-temperature FFA wash buffer (composed of 1x PBS and 0.05% Triton X-100). 105 Plates were incubated for 1 h at room temperature with 50 μ L/well of peroxidase-conjugated secondary antibody 106 (Bethyl Laboratories, A90216P) diluted 4000-fold in FFA staining buffer. Following secondary incubation plates were 107 then washed three times with 150 µL room-temperature FFA wash buffer. Plates were developed with 50 µL 108 TrueBlue peroxidase substrate (KPL, 5510-0054) for 15 minutes at room temperature. Development was stopped 109 by washing three times with 150 µL room-temperature deionized water, and the plates were dried for 10-15 110 minutes to minimize visual artifacts from liquid. 111 Imaging and counting Plates were scanned and counted on the S6 Universal M2 ImmunoSpot analyzer (Cellular 112 Technology Ltd, Cleveland, OH). See supplementary information for counting settings. Counts were used to 113 determine percent foci reduction at each dilution. For each specimen, the response between percent foci reduction 114 and serum dilution was modeled via 4-parameter logistic regression (Supplementary Material), which was used to 115 obtain ND50 and ND80 values. 116 117 Results 118 Assay Accuracy 119 To determine if RSV FRNT results closely reflected binding antibody titers, we tested remnant rubella 120 serology specimens and contrived serum samples via RSV FRNT and anti-RSV IgG indirect ELISA testing 121 (Supplementary Methods), with the expectation that specimens with higher ND50 values would have higher anti-122 RSV antibody titers by ELISA [25]. We prepared a "linearity panel" of six contrived specimens derived from NR-123 21973 reference serum with theoretical ND50 values ranging from 15-14,982 (Supplemental Methods). We tested 124 these alongside 22 remnant rubella serology specimens. RSV FRNT ND50 values of linearity panel members were 125 positively correlated (p = 1, p = 0.0014) with the level of RSV-reactive antibodies detected by ELISA (Figure 1A). All

126 22 rubella serology specimens tested positive for neutralizing antibodies by FRNT, with ND50 values spanning the 127 full range of measurable ND50 values between the lowest to highest serum dilutions (20-4,860). Similarly, 21 of 22 128 rubella serology specimens were positive for RSV-reactive antibodies by ELISA based on the manufacturer's cutoff. 129 The one remnant rubella serology specimen that fell just below the ELISA positive cutoff had an ND50 of 864. An Ig-130 depleted control exhibited an ND50 < 20 in the RSV FRNT assay and fell below the ELISA positive cutoff (Figure 1A). 131 We next compared ND50 values of our RSV FRNT assay with an independent reference assay on 132 commercially available sera and standardized results o the First International Standard for Antiserum to Respiratory 133 Syncytial Virus (NIBSC code: 16/284) [26]. RSV FRNT results were within 2-fold of previously published values (Table 134 1) [26]. FRNT results were also within 2-fold of proposed reference measurements when using RSV strain B 135 WV/14617/85 (Table 2) 6/13/2024 10:32:00 AM. The conversion factor for RSV A2 and RSV B FRNT ND50 units to 136 IU/mL was 0.37 and 0.91, respectively. 137 138 Assay Linearity, Precision, Reportable Range, and Limits of Quantitation 139 We next analyzed ND50 and ND80 results from the linearity panel by linear regression. Linearity panel 140 ND50 and ND80 results within or near the assay lowest and highest dilutions (20-4.860) were strongly linear (R^2 > 141 0.9), with slopes of 1.00 and 1.05, respectively. This met our assay acceptance criteria of $R^2 > 0.9$ and slope 142 between 0.9 and 1.1 (Figure 1B, Table S2). 143 We established our maximum acceptable geometric coefficient of variation (GCV) to be 37%, based on 144 CLSI and FDA requirements [28], and precision criteria of similar assays [29–39] (see Supplemental Material for 145 further discussion). To estimate intra-assay, inter-assay, and overall imprecision, we ran four linearity panel 146 specimens (in duplicate over 3 days, Figure 1C) and five rubella serology specimens (in duplicate over 2 days, Figure 147 1D). No specimen, clinical or contrived, exhibited intra-assay, inter-assay, or overall GCV above 37% (Table S3 and 148 S4). Measurements on reference serum using RSV B WV/14617/85 as a challenge virus also had GCV < 37% (Table 149 S5). 150 Per the precision analysis, ND50 and ND80 GCV was < 37% near the minimum and maximum dilutions (20 151 and 4,860), and assay measurements were linear through this range. Thus, the lower limit of quantitation and

upper limit of quantitation of the assay were determined to be 20 and 4,860, respectively, for both ND50 and

153 ND80. To verify values above the analytical measurement range, we prepared four dilutions of NR-21973 (ND50

- 154 29,963) and recovered values within 1.2-fold of original ND50 values (Supplementary Material, Table S6).
- 155

156 Comparison of 2021-2023 RSV neutralization titers associated with RSV outbreaks

157To investigate the role of population-level immune debt in the winter 2022 RSV outbreak, we determined158the geometric mean titer (GMT, geometric mean of ND50 measurements) of a repeated cross-sectional collection159of 193 remnant sera sent for clinical HSV western blot testing sampled across four discrete timepoints between1602022-2023: after 2021 RSV outbreak (February 2022), before (August 2022) and after (February 2022) 2022 RSV-161outbreak, and before 2023 RSV outbreak (September 2023, Figure 2). We found no significant difference in GMT or

162 median geometric titer between any combination of the four timepoints (one-way ANOVA, p = 0.86). Moreover,

163 samples collected before and after the 2022 RSV outbreak exhibited no significant difference in GMT (Wilcoxon

164 ranked-sum test, p = 0.68, Figure 2). In addition to the cross-sectional remnant HSV sera, we tested RSV

neutralizing titers of a separate group of remnant HSV serology serum specimens from 26 individuals who tested
 PCR positive for RSV after serum collection (by 25 – 463 days), referred to as future-RSV-PCR-positives. The overall
 GMT from these individuals was not significantly different from the cross-sectional sera for which RSV PCR testing
 data was not available (two-sided t-test, p = 0.24, Figure 3).

169 To further profile neutralizing titers in individuals testing PCR positive or negative for RSV, we collected 170 remnant sera from UW Medicine patients who had recently (within 3 months of sampling) tested PCR positive for 171 RSV (n=29) or PCR negative for RSV and positive for influenza virus (n=10) during the 2023-2024 respiratory season 172 (Figure 3). The PCR positive RSV group included 9 immunosuppressed individuals based on chart review and were 173 separated into their own group for this analysis. Population GMT (combined cross-sectional HSV serology remnant 174 specimens sets described above) was 4.2-fold lower than immunocompetent RSV PCR positive individuals (two-175 sided t-test, p = 0.51), 4.1-fold higher than that of RSV PCR positive immunosuppressed individuals (p = 0.008), and 176 2.14-fold higher than that of influenza PCR-positive, RSV PCR-negative individuals (p = 0.04). The future-RSV-PCR-177 positive samples had a GMT 4.7-fold higher than PCR positive, immunosuppressed individuals (p = 0.03) and 3.5-178 fold lower than PCR positive individuals without immunosuppression (p = 0.24). Immunocompetent RSV PCR 179 positive individuals had a GMT 17.4-fold higher than that of RSV PCR positive immunosuppressed individuals (p =

- 180 0.007), and 9.14-fold higher than Influenza PCR-positive, RSV PCR-negative individuals (p= 0.09). Thus, the
- 181 measurements obtained by RSV FRNT align with patient medical background and can represent individuals ranging
- 182 from the recently infected and immunocompetent to the immunosuppressed.
- 183

206

184 Discussion

Here, we designed and validated a high-throughput RSV neutralization assay amenable to clinical testing,
clinical trials, and seroprevalence studies. As a precise, sensitive, and linear assay standardizable to the NIBSC
16/284 RSV neutralizing reference material, RSV FRNT is an alternative to reporter virus methods, allowing for
similar throughput, quantification, and precision unlimited by development of recombinant viruses. The potential
to use wild-type strains as challenge viruses also enables monitoring for nirsevimab resistance and vaccine evasion
by RSV, which are potential concerns given the antigenic variability of the RSV F-protein [40–42], continued vaccine
roll-out[4], and recent identification of RSV strains resistant to nirsevimab[43,44].

192 Our assay had similar if not improved precision compared to other assays [29–34]. Our RSV FRNT differs 193 from most other assays with a somewhat lower upper AMR limit of only 4,860 (ND50 or ND80) [45]. Given that 194 only 2.6% (n=6/226) of tested clinical specimens exhibit a neutralizing titer (NT)> 10.000, we found the increased 195 throughput more desirable. We also standardized our RSV FRNT to the First International Standard for Antiserum to 196 Respiratory Syncytial Virus strains A and B, which has been reported for select assays [24]. Our RSV A2 conversion 197 factor of 0.37 is very similar to the 0.38 conversion factor used in a 2021 RSV vaccine clinical trial [46]. In contrast, 198 the RSV A conversion factor from another study was 0.88 [26]. The higher conversion factor is most likely explained 199 by key differences in assay methodology, such as challenge virus, target cell line, and assay readout [24,45]. Our 200 RSV B conversion factor was 0.91, similar to the average conversion factor of 1.1 calculated from NIBSC [27]. 201 We found no significant difference in neutralizing titer between individuals serums sampled pre- and post-202 RSV 2022 outbreak, unlike earlier studies which found evidence of reduced anti-RSV neutralizing titer during the 203 COVID-19 pandemic [11,47]. In agreement with our findings, a 2022 population-immunosurveillance study using 204 methods similar to ours also could not detect waning antibody immune response prior to RSV resurgence [48]. 205 Moreover, a recent study attributed approximately two-thirds of the increase in RSV cases to significant increases in

volume of RSV testing [49]. Other possible theories behind post-pandemic RSV resurgence, such as SARS-CoV-2-

induced immune dysregulation [50–53], changes in population-wide health-seeking behavior [54], and loosening of
 public health safety measures [8] should also be investigated to inform future vaccination and immunotherapeutic
 development.

210 Limitations of this study include its cross-sectional design and convenience sampling of remnant clinical 211 specimens for validation. Measurement of pre-and post-outbreak RSV neutralizing titers were limited by the 212 sample size (n=227). Our sample group lacked infants (n=0) and had a limited number of elderly individuals (n=22, 213 12.4%), both of which are especially vulnerable to lowered anti-RSV immunity and severe RSV symptoms[2,57,58]. 214 Patients with no reported RSV infection might have experienced unreported RSV infection from the smaller 215 outbreak of winter 2021, potentially inflating neutralizing titers and confounding comparison of pre- and post-2022 216 outbreak populations. RSV strains A2 and B WV/14617/85, classically used for FRNT and PRNT validation[24], were 217 used instead of more contemporary and/or clinical isolates in circulation during the 2022-2023 pandemic[59–61]. 218 Differences in sample handling may have influenced measurements. For example, we noticed that GMT across sera 219 of RSV PCR-positive individuals (without immunosuppression) sourced from one hospital trended lower compared 220 to those from the two other hospitals used in the study by 4.43-fold and 2.55-fold respectively, although this 221 difference did not reach statistical significance. 222 Our findings establish the RSV FRNT assay as a high-throughput, accurate neutralization assay sufficiently 223 sensitive to distinguish immunosuppressed and seroconverted individuals from the general population, a 224 diagnostic necessity given the upcoming release of the RSV vaccine. Our immunosurveillance study using this assay 225 found no evidence of immune debt, underlining the uncertainty behind drivers of RSV epidemiology and RSV 226 antibody dynamics, an ever-more concerning gap in knowledge considering the eventuality of the next viral 227 pandemic. 228 229 Acknowledgments 230 We thank Dr. Stephanie Goya for insightful discussion and writing assistance. This research received no

231 specific funding and was supported by departmental funds.

233 Conflict of interest

- ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research
- 235 support from Gilead, outside of the described work.

236

238 Bibliography

- Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious
 Diseases, (2022). https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial virus-rsv (accessed June 10, 2023).
- L.J. Anderson, P.R. Dormitzer, D.J. Nokes, R. Rappuoli, A. Roca, B.S. Graham, Strategic
 priorities for respiratory syncytial virus (RSV) vaccine development, Vaccine 31 (2013)
 B209–B215. https://doi.org/10.1016/j.vaccine.2012.11.106.
- [3] R.D. De Vries, R.L. De Swart, Antibodies face the challenge against human respiratory
 syncytial virus, Cell Host Microbe 31 (2023) 135–136.
- 247 https://doi.org/10.1016/j.chom.2022.12.010.
- [4] O. of the Commissioner, FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine, FDA
 (2023). https://www.fda.gov/news-events/press-announcements/fda-approves-first respiratory-syncytial-virus-rsv-vaccine (accessed June 12, 2023).
- [5] G. Pruccoli, E. Castagno, I. Raffaldi, M. Denina, E. Barisone, L. Baroero, F. Timeus, I.
 Rabbone, A. Monzani, G.M. Terragni, C. Lovera, A. Brach del Prever, P. Manzoni, M.
 Barbaglia, L. Roasio, S. De Franco, C. Calitri, M. Lupica, E. Felici, C. Marciano, S. Santovito,
 G. Militerno, E. Abrigo, A. Curtoni, P. Quarello, C. Bondone, S. Garazzino, The Importance of
 RSV Epidemiological Surveillance: A Multicenter Observational Study of RSV Infection
 during the COVID-19 Pandemic, Viruses 15 (2023) 280.
- 257 https://doi.org/10.3390/v15020280.
- M.-N. Billard, L.J. Bont, Quantifying the RSV immunity debt following COVID-19: a public
 health matter, Lancet Infect. Dis. 23 (2023) 3–5. https://doi.org/10.1016/S14733099(22)00544-8.
- [7] I. Garg, R. Shekhar, A.B. Sheikh, S. Pal, Impact of COVID-19 on the Changing Patterns of
 Respiratory Syncytial Virus Infections, Infect. Dis. Rep. 14 (2022) 558–568.
 https://doi.org/10.3390/idr14040059.
- Y.-C. Chuang, K.-P. Lin, L.-A. Wang, T.-K. Yeh, P.-Y. Liu, The Impact of the COVID-19 Pandemic
 on Respiratory Syncytial Virus Infection: A Narrative Review, Infect. Drug Resist. 16 (2023)
 661–675. https://doi.org/10.2147/IDR.S396434.
- P.A. Jorquera, L. Anderson, R.A. Tripp, Understanding respiratory syncytial virus (RSV)
 vaccine development and aspects of disease pathogenesis, Expert Rev. Vaccines 15 (2016)
 173–187. https://doi.org/10.1586/14760584.2016.1115353.
- [10] D. Sun, A. Hsu, J. Quiroz, X. He, M.C. Whiteman, K.B. Gurney, S. Dellatore, Development
 and comparison of three cell-based potency assays for anti-respiratory syncytial virus
 monoclonal antibody, Biologicals 74 (2021) 1–9.
- 273 https://doi.org/10.1016/j.biologicals.2021.10.001.
- [11] F. Reicherz, R.Y. Xu, B. Abu-Raya, A. Majdoubi, C. Michalski, L. Golding, A. Stojic, M. Vineta,
 M. Granoski, Z. Cieslak, A. Chacko, N. Desai, I. Sekirov, D.J. Marchant, P.M. Lavoie, Waning
 Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019
 Pandemic, J. Infect. Dis. 226 (2022) 2064–2068. https://doi.org/10.1093/infdis/jiac192.
- 278 [12] S.R. Vaidya, Immuno-Colorimetric Neutralization Test: A Surrogate for Widely Used Plaque
- 279 Reduction Neutralization Tests in Public Health Virology, Viruses 15 (2023) 939.
 280 https://doi.org/10.3390/v15040939.

- 281 [13] K. S, H. L, S. A.F, P. A, Establishing Correlates of Protection for Vaccine Development:
- 282 Considerations for the Respiratory Syncytial Virus Vaccine Field, Viral Immunol. (2018).
 283 https://doi.org/10.1089/vim.2017.0147.
- [14] W.P. Glezen, A. Paredes, J.E. Allison, L.H. Taber, A.L. Frank, Risk of respiratory syncytial virus
 infection for infants from low-income families in relationship to age, sex, ethnic group, and
 maternal antibody level, J. Pediatr. 98 (1981) 708–715. https://doi.org/10.1016/s0022 3476(81)80829-3.
- [15] K.A. Ward, P.R. Lambden, M.M. Ogilvie, P.J. Watt, Antibodies to respiratory syncytial virus
 polypeptides and their significance in human infection, J. Gen. Virol. 64 (Pt 9) (1983) 1867–
 1876. https://doi.org/10.1099/0022-1317-64-9-1867.
- [16] T.M. de Sierra, M.L. Kumar, T.E. Wasser, B.R. Murphy, E.K. Subbarao, Respiratory syncytial
 virus-specific immunoglobulins in preterm infants, J. Pediatr. 122 (1993) 787–791.
 https://doi.org/10.1016/s0022-3476(06)80027-2.
- [17] L.G. Stensballe, H. Ravn, K. Kristensen, K. Agerskov, T. Meakins, P. Aaby, E.A.F. Simões,
 Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus
 hospitalization, and recurrent wheeze, J. Allergy Clin. Immunol. 123 (2009) 398–403.
 https://doi.org/10.1016/j.jaci.2008.10.043.
- [18] L.G. Stensballe, H. Ravn, K. Kristensen, T. Meakins, P. Aaby, E.A.F. Simoes, Seasonal
 Variation of Maternally Derived Respiratory Syncytial Virus Antibodies and Association with
 Infant Hospitalizations for Respiratory Syncytial Virus, J. Pediatr. 154 (2009) 296-298.e1.
 https://doi.org/10.1016/j.jpeds.2008.07.053.
- S.R. Vaidya, D.W.G. Brown, L. Jin, D. Samuel, N. Andrews, K.E. Brown, Development of a
 focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing
 antibodies, J. Virol. Methods 163 (2010) 153–156.
- 305 https://doi.org/10.1016/j.jviromet.2009.09.006.
- 306 [20] Cohen: Plaque reduction neutralization test for measles... Google Scholar, (n.d.).
- 307https://scholar.google.com/scholar_lookup?title=Plaque+reduction+neutralization+test+fo308r+measles+antibodies:+Description+of+a+standardised+laboratory+method+for+use+in+i309mmunogenicity+studies+of+aerosol+vaccination&author=Cohen,+B.J.&author=Audet,+S.&310author=Andrews,+N.&author=Beeler,+J.&author=WHO+working+group+on+measles+plaq311ue+reduction+neutralization+test&publication_year=2007&journal=Vaccine&volume=26&312pages=59%E2%80%9366&doi=10.1016/j.vaccine.2007.10.046 (accessed September 1,3132023).
- S.R. Vaidya, N.S. Kumbhar, V.S. Bhide, Detection of measles, mumps and rubella viruses by
 immuno-colorimetric assay and its application in focus reduction neutralization tests,
 Microbiol. Immunol. 58 (2014) 666–674. https://doi.org/10.1111/1348-0421.12201.
- [22] Z. Wen, M. Citron, A.J. Bett, A.S. Espeseth, K.A. Vora, L. Zhang, D.J. DiStefano, Development
 and application of a higher throughput RSV plaque assay by immunofluorescent imaging, J.
 Virol. Methods 263 (2019) 88–95. https://doi.org/10.1016/j.jviromet.2018.10.022.
- Y. Tanino, K. Nishioka, C. Yamamoto, Y. Watanabe, T. Daidoji, M. Kawamoto, S. Uda, S.
 Kirito, Y. Nakagawa, Y. Kasamatsu, Y. Kawahara, Y. Sakai, S. Nobori, T. Inaba, B. Ota, N.
 Fujita, A. Hoshino, Y. Nukui, T. Nakaya, Emergence of SARS-CoV-2 with Dual-Drug Resistant
 Mutations During a Long-Term Infection in a Kidney Transplant Recipient, Infect. Drug
 Resist. 17 (2024) 531–541. https://doi.org/10.2147/IDR.S438915.

325 [24] R. Raghunandan, D. Higgins, N. Hosken, RSV neutralization assays – Use in immune

- 326 response assessment, Vaccine 39 (2021) 4591–4597.
- 327 https://doi.org/10.1016/j.vaccine.2021.06.016.
- 328 [25] G.J. Xu, T. Kula, Q. Xu, M.Z. Li, S.D. Vernon, T. Ndung'u, K. Ruxrungtham, J. Sanchez, C.
 329 Brander, R.T. Chung, K.C. O'Connor, B. Walker, H.B. Larman, S.J. Elledge, Comprehensive
 330 serological profiling of human populations using a synthetic human virome, Science 348
 331 (2015) aaa0698. https://doi.org/10.1126/science.aaa0698.
- [26] M.C. Crank, T.J. Ruckwardt, M. Chen, K.M. Morabito, E. Phung, P.J. Costner, L.A. Holman,
 S.P. Hickman, N.M. Berkowitz, I.J. Gordon, G.V. Yamshchikov, M.R. Gaudinski, A. Kumar, L.A.
 Chang, S.M. Moin, J.P. Hill, A.T. DiPiazza, R.M. Schwartz, L. Kueltzo, J.W. Cooper, P. Chen, J.A.
 Stein, K. Carlton, J.G. Gall, M.C. Nason, P.D. Kwong, G.L. Chen, J.R. Mascola, J.S. McLellan,
 J.E. Ledgerwood, B.S. Graham, THE VRC 317 STUDY TEAM, A proof of concept for structurebased vaccine design targeting RSV in humans, Science 365 (2019) 505–509.
- 338 https://doi.org/10.1126/science.aav9033.
- J.U. McDonald, P. Rigsby, E. Atkinson, O.G. Engelhardt, Expansion of the 1st WHO
 international standard for antiserum to respiratory syncytial virus to include neutralisation
 titres against RSV subtype B: An international collaborative study, Vaccine 38 (2020) 800–
 807. https://doi.org/10.1016/j.vaccine.2019.10.095.
- 343 [28] E.M. Burd, Validation of Laboratory-Developed Molecular Assays for Infectious Diseases,
 344 Clin. Microbiol. Rev. 23 (2010) 550–576. https://doi.org/10.1128/cmr.00074-09.
- J. Merluza, J. Ung, K. Makowski, A. Robinson, K. Manguiat, N. Mueller, J. Audet, J.C.-Y.
 Chen, J.E. Strong, H. Wood, A. Bello, Validation and Establishment of the SARS-CoV-2
 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction
 Neutralization Test, Microbiol. Spectr. 11 (2023) e0378922.
 https://doi.org/10.1128/cpactrum.02780.22
- 349 https://doi.org/10.1128/spectrum.03789-22.
- [30] K.S. Omland, A. Brys, D. Lansky, K. Clement, F. Lynn, Participating Laboratories,
 Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for
 assessment of functional antibodies in multiple species, Clin. Vaccine Immunol. CVI 15
 (2008) 946–953. https://doi.org/10.1128/CVI.00003-08.
- [31] S. Kostense, S. Moore, A. Companjen, A.B.H. Bakker, W.E. Marissen, R. von Eyben, G.J.
 Weverling, C. Hanlon, J. Goudsmit, Validation of the Rapid Fluorescent Focus Inhibition
 Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples, Antimicrob. Agents
 Chemother. 56 (2012) 3524–3530. https://doi.org/10.1128/AAC.06179-11.
- [32] K. Bohning, S. Sonnberg, H.-L. Chen, M. Zahralban-Steele, T. Powell, G. Hather, H.K. Patel,
 H.J. Dean, A high throughput reporter virus particle microneutralization assay for
 quantitation of Zika virus neutralizing antibodies in multiple species, PLOS ONE 16 (2021)
 e0250516. https://doi.org/10.1371/journal.pone.0250516.
- [33] S.E. Larsen, B.J. Berube, T. Pecor, E. Cross, B.P. Brown, B.D. Williams, E. Johnson, P. Qu, L.
 Carter, S. Wrenn, E. Kepl, C. Sydeman, N.P. King, S.L. Baldwin, R.N. Coler, Qualification of
 ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using
 human clinical samples, J. Immunol. Methods 499 (2021) 113160.
- 366 https://doi.org/10.1016/j.jim.2021.113160.

367 [34] E.E. Rhoden, B.A. Mainou, J.L. Konopka-Anstadt, M.S. Oberste, An automated high-

- 368throughput enterovirus D68 microneutralization assay platform, J. Virol. Methods 308369(2022) 114590. https://doi.org/10.1016/j.jviromet.2022.114590.
- [35] E. Santana-Rodríguez, M.K. Méndez-Orta, T. Sardina-González, M. Pilar, S.C.- Brizuela, Y.
 Sordo-Puga, D. Pérez-Pérez, A. Oliva-Cárdenas, M. Vargas-Hernández, C.A. Duarte, M.T.
 Frías-Lepoureaux, M. Suárez-Pedroso, Consistency of the Neutralizing Peroxidase Linked
 Assay for Classical Swine Fever and Homologation with an OIE Reference Laboratory,
 (2022).
- [36] M. Zhu, S. Cloney-Clark, S. Feng, A. Parekh, D. Gorinson, D. Silva, P. Skonieczny, A. Wilson,
 R. Kalkeri, W. Woo, M.R. Cai, L. Fries, G. Glenn, J.S. Plested, A Severe Acute Respiratory
 Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for
 Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection,
 Microorganisms 11 (2023) 1789. https://doi.org/10.3390/microorganisms11071789.
- [37] Pan Y.B., Zhang N., Zhan S.S., Gui F., Wang J., Song G., Wu X.L., Yang X.M., Establishment
 and validation of competitive ELISA for detecting blocking activity of monoclonal antibody
 against SARS-CoV-2 RBD, Chin. J. New Drugs (2020) 2496–2501.
- [38] M.E. Bonhomme, C.J. Bonhomme, L. Strelow, A. Chaudhari, A. Howlett, C. Breidenbach, J.
 Hester, C. Hammond, M. Fuzy, L. Harvey, V. Swanner, J. Ellis, R.R. Greway, V.A. Pisciella, T.
 Green, L. Kierstead, Robust validation and performance comparison of immunogenicity
 assays assessing IgG and neutralizing antibodies to SARS-CoV-2, PLOS ONE 17 (2022)
 e0262922. https://doi.org/10.1371/journal.pone.0262922.
- [39] T.M. Timiryasova, P. Luo, L. Zheng, A. Singer, R. Zedar, S. Garg, C. Petit, S. Moore, B.T. Hu, M.
 Brown, Rapid fluorescent focus inhibition test optimization and validation: Improved
 detection of neutralizing antibodies to rabies virus, J. Immunol. Methods 474 (2019)
 112626. https://doi.org/10.1016/j.jim.2019.06.017.
- [40] A.M. Hause, D.M. Henke, V. Avadhanula, C.A. Shaw, L.I. Tapia, P.A. Piedra, Sequence
 variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and
 historical genotypes of RSV/A and RSV/B, PLoS ONE 12 (2017) e0175792.
 https://doi.org/10.1371/journal.pone.0175792.
- [41] S. Vandini, C. Biagi, M. Lanari, Respiratory Syncytial Virus: The Influence of Serotype and
 Genotype Variability on Clinical Course of Infection, Int. J. Mol. Sci. 18 (2017) 1717.
 https://doi.org/10.3390/ijms18081717.
- J.A. Melero, M.L. Moore, Influence of Respiratory Syncytial Virus Strain Differences on
 Pathogenesis and Immunity, in: L.J. Anderson, B.S. Graham (Eds.), Chall. Oppor. Respir.
 Syncytial Virus Vaccines, Springer, Berlin, Heidelberg, 2013: pp. 59–82.
- 402 https://doi.org/10.1007/978-3-642-38919-1_3.
- 403 [43] S.C.J. Jorgensen, Nirsevimab: review of pharmacology, antiviral activity and emerging
 404 clinical experience for respiratory syncytial virus infection in infants, J. Antimicrob.
 405 Chemother. 78 (2023) 1143–1149. https://doi.org/10.1093/jac/dkad076.
- 406 [44] A.C. Langedijk, E.R. Harding, B. Konya, B. Vrancken, R.J. Lebbink, A. Evers, J. Willemsen, P.
 407 Lemey, L.J. Bont, A systematic review on global RSV genetic data: Identification of
 408 knowledge gaps, Rev. Med. Virol. 32 (2022) e2284. https://doi.org/10.1002/rmv.2284.
- 409 [45] N. Hosken, B. Plikaytis, C. Trujillo, K. Mahmood, D. Higgins, A multi-laboratory study of 410 diverse RSV neutralization assays indicates feasibility for harmonization with an

- 411 international standard, Vaccine 35 (2017) 3082–3088.
- 412 https://doi.org/10.1016/j.vaccine.2017.04.053.
- [46] E.E. Walsh, A.R. Falsey, D.A. Scott, A. Gurtman, A.M. Zareba, K.U. Jansen, W.C. Gruber, P.R.
 Dormitzer, K.A. Swanson, D. Radley, E. Gomme, D. Cooper, B. Schmoele-Thoma, for the
- 415 C3671001 Study Group, A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus 416 Prefusion F Vaccine, J. Infect. Dis. 225 (2022) 1357–1366.
- 417 https://doi.org/10.1093/infdis/jiab612.
- 418 [47] G. den Hartog, P.B. van Kasteren, R.M. Schepp, A.C. Teirlinck, F.R.M. van der Klis, R.S. van
 419 Binnendijk, Decline of RSV-specific antibodies during the COVID-19 pandemic, Lancet
 420 Infect. Dis. 23 (2023) 23–25. https://doi.org/10.1016/S1473-3099(22)00763-0.
- [48] G. Walker, C. Foster, A. Sevendal, A. Domazetovska, A. Kamalakkannan, P.C.M. Williams,
 K.W. Kim, A. Condylios, S. Stelzer-Braid, A. Bartlett, W. Rawlinson, Genomic and
 Immunological Characterisation Shows Increased Respiratory Syncytial Virus Cases Not
 Due to Waning Antibody Mediated Immunity, (2023).
- 425 https://doi.org/10.2139/ssrn.4515871.
- 426 [49] B.A. Petros, C.E. Milliren, P.C. Sabeti, A. Ozonoff, Increased pediatric RSV case counts
 427 following the emergence of SARS-CoV-2 are attributable to increased testing, (2024)
 428 2024.02.06.24302387. https://doi.org/10.1101/2024.02.06.24302387.
- [50] B. Kratzer, D. Trapin, P. Ettel, U. Körmöczi, A. Rottal, F. Tuppy, M. Feichter, P. Gattinger, K.
 Borochova, Y. Dorofeeva, I. Tulaeva, M. Weber, K. Grabmeier-Pfistershammer, P.A. Tauber,
 M. Gerdov, B. Mühl, T. Perkmann, I. Fae, S. Wenda, H. Führer, R. Henning, R. Valenta, W.F.
 Pickl, Immunological imprint of COVID-19 on human peripheral blood leukocyte
 populations, Allergy 76 (2021) 751–765. https://doi.org/10.1111/all.14647.
- 434 [51] Y. Jing, L. Luo, Y. Chen, L.S. Westerberg, P. Zhou, Z. Xu, A.A. Herrada, C.-S. Park, M. Kubo, H.
 435 Mei, Y. Hu, P.P.-W. Lee, B. Zheng, Z. Sui, W. Xiao, Q. Gong, Z. Lu, C. Liu, SARS-CoV-2 infection
 436 causes immunodeficiency in recovered patients by downregulating CD19 expression in B
 437 cells via enhancing B-cell metabolism, Signal Transduct. Target. Ther. 6 (2021) 1–13.
 438 https://doi.org/10.1038/s41392-021-00749-3.
- [52] J. Liu, X. Yang, H. Wang, Z. Li, H. Deng, J. Liu, S. Xiong, J. He, X. Feng, C. Guo, W. Wang, G.
 Zelinskyy, M. Trilling, K. Sutter, T. Senff, C. Menne, J. Timm, Y. Zhang, F. Deng, Y. Lu, J. Wu,
 M. Lu, D. Yang, U. Dittmer, B. Wang, X. Zheng, Analysis of the Long-Term Impact on Cellular
 Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment,
- 443 mBio 12 (2021) 10.1128/mbio.00085-21. https://doi.org/10.1128/mbio.00085-21.
- [53] C. Phetsouphanh, D.R. Darley, D.B. Wilson, A. Howe, C.M.L. Munier, S.K. Patel, J.A. Juno,
 L.M. Burrell, S.J. Kent, G.J. Dore, A.D. Kelleher, G.V. Matthews, Immunological dysfunction
 persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, Nat.
 Immunol. 23 (2022) 210–216. https://doi.org/10.1038/s41590-021-01113-x.
- 448 [54] B. Abu-Raya, M.V. Paramo, F. Reicherz, P.M. Lavoie, Why has the epidemiology of RSV
 449 changed during the COVID-19 pandemic?, eClinicalMedicine 61 (2023).
 450 https://doi.org/10.1016/j.eclinm.2023.102089.
- [55] C. j. Sande, M. n. Mutunga, E. a. Okiro, G. f. Medley, P. a. Cane, D. j. Nokes, Kinetics of the
 Neutralizing Antibody Response to Respiratory Syncytial Virus Infections in a Birth Cohort,
 J. Med. Virol. 85 (2013) 2020–2025. https://doi.org/10.1002/jmv.23696.

[56] B.N. Blunck, L. Aideyan, X. Ye, V. Avadhanula, L. Ferlic-Stark, L. Zechiedrich, B.E. Gilbert, P.A. Piedra, A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas, Vaccine 39 (2021) 1248–1256. https://doi.org/10.1016/j.vaccine.2021.01.045. [57] R.T. Stein, H.J. Zar, RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future, Pediatr. Pulmonol. 58 (2023) 1631–1639. https://doi.org/10.1002/ppul.26370. [58] L.M. Stephens, S.M. Varga, Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population, Vaccines 9 (2021) 624. https://doi.org/10.3390/vaccines9060624. [59] M. Redlberger-Fritz, D.N. Springer, S.W. Aberle, J.V. Camp, J.H. Aberle, Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID-19 pandemic, J. Med. Virol. 95 (2023) e28830. https://doi.org/10.1002/jmv.28830. [60] S. Goya, J. Sereewit, D. Pfalmer, T.V. Nguyen, S.A.K.M. Bakhash, E.B. Sobolik, A.L. Greninger, Genomic Characterization of Respiratory Syncytial Virus during 2022-23 Outbreak, Washington, USA, Emerg. Infect. Dis. 29 (2023) 865-868. https://doi.org/10.3201/eid2904.221834. [61] G. Adams, G.K. Moreno, B.A. Petros, R. Uddin, Z. Levine, B. Kotzen, K. Messer, S.T. Dobbins, K.C. DeRuff, C. Loreth, T. Brock-Fisher, S.F. Schaffner, S. Chaluvadi, S. Kanjilal, J. Luban, A. Ozonoff, D. Park, S. Turbett, K.J. Siddle, B.L. MacInnis, P. Sabeti, J.E. Lemieux, RSV Surge in the USA and Viral Lineages, 2022, N. Engl. J. Med. 388 (2023) 1335–1337. https://doi.org/10.1056/NEJMc2216153. [62] RSV State Trends - NREVSS | CDC, (2024). https://www.cdc.gov/surveillance/nrevss/rsv/state.html (accessed February 27, 2024).

498	Table 1: ND50 values, expressed in IU/mL, obtained by the RSV FRNT assay using RSV A2 as the challenge virus
499	are within 2-fold of independent published estimates.

	-	-		
sample	n	ND50 RSV FRNT (IU/mL) ^{a,c}	ND50 reference (IU/mL) ^{b,c}	ratio of ND50 RSV FRNT / reference
NR-21973	5	9,539	6,830	1.4
NR-4020	5	1,392	1,236	1.1
NR-4021	6	4,154	4,404	0.9
NR-4022	6	898	706	1.3
NR-4023	12	1,114	625	1.8

^aNIBSC 16/284 standard was tested twelve times with RSV A2, with geometric mean 5404.8. To convert ND50 values to IU/mL, ND50 values obtained in the RSV FRNT assay are multiplied by 0.37.

^bReference values were taken from an independent publication, which used an IU/mL conversion factor of

503 0.88[26].

504 [°]Data represents the geometric mean.

- 505
- 506

507 Table 2: ND50 values, expressed in IU/mL, obtained by the RSV FRNT assay using RSV B WV/14617/85 as 508 challenge virus are within 2-fold of independent published estimates.

sample	n	ND50 RSV FRNT (IU/mL) ^{a,c}	ND50 reference (IU/mL) ^{b,c}	ratio of ND50 RSV FRNT / reference
NR-21973	6	1,107	1,005	1.1
NR-4022	6	13,738	12,059	1.1

^aNIBSC 16/284 standard was tested 6 times, with geometric mean 2,195.8. To convert ND50 values to IU/mL,

510 ND50 values obtained in the RSV FRNT assay are multiplied by 0.91. In the reference article, mean conversion

511 factor across all assays reported was 1.1; the reference did not report conversion factor per-assay[27].

^bReference values obtained from independent publication (no conversion factor provided)[27].

513 [°]Data represents the geometric mean.

514

516 Figure Legends

517 Figure 1. The RSV FRNT assay results are strongly correlated with ELISA measurements and meet our linearity 518 and precision requirements. A) Shown are the results of RSV-binding antibody measurement by ELISA of the 519 linearity panel specimens (black open circles; see Assay Accuracy), rubella serology remnant specimens (blue open 520 circles), and the Ig-depleted negative control (red closed circle, NR-49447). Dashed black line is the 4-parameter 521 logistic curve fit of the ELISA results from the linearity panel only ($R^2 = 0.96$). Sera was measured in duplicate, 522 normalized relative to the assay cutoff control (relative absorbance of ten), and plotted as average values. The 523 standard deviation of the measurements is plotted as a black line range. In most cases, the standard deviation was 524 smaller than the diameter of the plotted points obscuring the standard deviation line range. Values with relative 525 absorbance less than nine are considered negative since they fall below the cutoff. Values with relative absorbance 526 between 9 and 11 are inconclusive. Values with relative absorbance greater than 11 are positive for RSV-reactive 527 antibodies. B) RSV FRNT ND50 and ND80 values from testing of the linearity panel. The range of mean ND50 results 528 include from 15.1 to 16,093.2 and the range of mean ND80 results include from 14.9 to 5308.7. The dashed lines 529 (black for ND50 and blue for ND80) are the best fit from the linear regression analysis. C) Linearity panel specimens 530 (the same used in panel A and B) ranging in expected ND50 values from 55 to 14,982, were measured in duplicate 531 over 3 days. Every sample exhibited GCV < 37%, meeting our acceptance criteria for precision. Green boxes 532 demarcate boundaries of expected variation for a GCV of 37%. Solid lines represent mean ND50 for panel member. 533 D) Five serum specimens from rubella remnant testing with known ND50s/ND80s spanning the AMR of the assay 534 were selected and tested in duplicate over two days. Every sample exhibited GCV < 37%, meeting our acceptance 535 criteria for precision. Green boxes demarcate boundaries of expected variation for a GCV of 37%. Solid lines 536 represent mean ND50 for panel member.

537

Figure 2. Distribution of neutralizing titers among random population samples collected from late 2021 to early
2024. A) The ND50 neutralizing titer results of HSV serology remnant serum specimens from individuals sampled
around February 2022, August 2022, February 2023, and September 2023, with date of serum collection on x-axis.
For each cross-sectional group, dashed and solid lines represent geometric median and geometric mean,

respectively. B) Number of positive RSV antigen tests across time. Data obtained from CDC Washington State

trends[62], reported as 5 week average. Log₂-transformed data was analyzed, using a two-sided student's T-test to
compare groups pairwise.

545

546	Figure 3. Distribution of neutralizing titers among RSV negative, positive, and future-infected individuals relative
547	to a random population sample. ND50 neutralizing titer for individuals sampled from October 2021 to February
548	2024. Solid lines represent geometric mean. HSV serology remnant specimens: a random population sample of
549	remnant sera sent for clinical HSV remnant testing, collected from February 2021 to September 2023, with
550	unknown testing status for RSV. Future RSV-infected: HSV remnant samples (not part of the HSV serology remnant
551	specimen group above) from individuals who tested positive for RSV 25 or more days after serum collection date.
552	RSV PCR+, immunocompetent: emergency department (ED) patients PCR-positive for RSV 98 days before to 7 days
553	after serum collection. RSV PCR+, immunosuppressed: ED patients PCR-positive for RSV 49 days before to 7 days
554	after serum collection, with medical status of immunosuppression at time of test/collection. Influenza+, RSV-: ED
555	patients with no recorded RSV-positive or immunosuppression status who tested PCR-positive for influenza 39 days
556	before to 7 days after serum collection. Log_2 -transformed data was analyzed, using a two-sided student's T-test to
557	compare groups pairwise.





